共找到 20 条结果
Acta Gastro-Enterologica Belgica has become a fully open-access Journal! This was our wish, shared by the Associate Editors and founding societies, the Société Royale Belge de Gastro-Entérologie (SRBGE) and the Vlaamse Vereniging voor Gastro-Enterologie (VVGE). We announced this major improvement during our Acta Gastro-Enterologica Belgica board meeting in Antwerpen in March 2020 (Picture). It is indeed very important for the Belgian and international scientific community to get easy access to all the Acta Gastro-Enterologica Belgica manuscripts. [...]
The history of Acta Gastro-Enterologica Belgica is long, rich… and cloudy. There is no centralised archive available. However, all currently active gastroenterologists in Belgium have been trained with the journal, have published abstracts or manuscripts in it, or at least know of its existence. Whereas it started as a national society's journal in 1933, it has grown to a competitive international journal with Impact Factor. We felt the need to reconstruct the journal's long history, since this was never done before. This review tried to highlight some of the important milestones, without claiming to be complete. Looking back helps to better foresee and anticipate the future.
Recently, public availability of medical manuscripts free of charge was subject to a national discussion, pledging for obligatory open access journals (1). The idea is based upon the fact that many researches in medical sciences are (partially) funded by the government, and thus by tax payers. Therefore, all tax payers should have free access to the published results. However, the traditional publishing model is based on authors submitting their research results free of charge to a medical journal, and when accepted and published, only subscribers to the journal are allowed access to its content. Commercial publishers are thus financed by the subscribers (libraries and individuals) to their journals and by selling publicity of pharmaceutical companies. Because of the high subscription rates more and more publishers embarked on the open access model, also known as the author-pays model (2). The principle of open access journals requires authors to pay for the publication of their accepted manuscript, which then becomes freely available to the world. It is currently unclear which of the two financial models is more profitable for the publishers. However, the number of open access journals is steadily increasing with new releases on a weekly base. And all these journals need manuscripts (and publication fees) to financially survive. SO. the open access model has led to the danger of predatory publishing with questionable journal integrity and problematic peer review process. [...]
暂无摘要（点击查看原文获取完整内容）
status: Accepted
暂无摘要（点击查看原文获取完整内容）
The article has been withdrawn at the request of the authors and editor because of incorrect authorship, which is considered a form of unethical publication. The Publisher apologizes for any inconvenience this may cause.
The article has been withdrawn at the request of the authors and editor because of incorrect authorship, which is considered a form of unethical publication. The Publisher apologizes for any inconvenience this may cause.
We read with attention the letter of Xavier Verhelst in the last issue of Acta Gastro-Enterologica Belgica evaluating the results of a screening campaign in Lendelede (1). Patients undergoing blood examination were offered anti-HCV screening, further HCV RNA evaluation and hepatology consultation if indicated. During one year, 560 patients were screened in a single center. Of those, 5 patients (0.9%) had antibodies against HCV. Positive RNA was evidenced in 3 patients (0.5%) and two of them were referred for antiviral treatment. Thanks to those data, the authors highlight the need of screening campaigns for HCV infection in Belgium (1). We also performed a screening campaign for HCV infection in our hospital. We proposed an HCV screening through a simple finger-stick test without any questionnaire to people (patients, visitors or health care providers) who were present in the main hall of our academic hospital during one day (April 25, 2018). Of 200 volunteers who had been tested during one day, 3 were positive (1.5%). All three patients (one woman and two men) explained that they were already aware of their status (one patient with a previous failure of interferon therapy, one with a previous effective antiviral treatment and another who did not provide any further information). All were middle-age people (50-60 years). There were no newly diagnosed cases and no subsequent antiviral treatment. [...]
The world is changing... the landscape of gastro- enterology and hepatology too. First, scientific knowledge is evolving. The complex mechanisms that explain liver and digestive diseases are becoming better and better characterized. In the previous issue of Acta Gastro-Enterologica Belgica, for example, we discovered the role of angiogenesis in non- alcoholic steatohepatitis, one of the most common liver diseases without drug treatment available to date. [...]
UNLABELLED: Upper gastrointestinal bleeding (UGIB) remains a common disease affecting 100 to 170 per 100 000 adults per year and causing thereby a significant burden to healthcare resources. Despite the improvements in the management of this disorder, the associated mortality ranges from 5 to 14%. Since the general management of UGIB is not uniform, the main objective of this work is to provide guidelines for the care of adults and children presenting with bleeding caused by gastro-duodenal ulcer or variceal rupture. METHODS: In the absence of evidence-based recommendations, these guidelines were proposed after expert opinions reconciliation and graded accordingly. They are based on the published literature up to September 2010 and graded according to the class of evidence. RESULTS: The current guidelines for the management of UGIB include recommendations for the diagnostic process, general supportive care, pharmacological therapy aiming at bleeding control, specific and endoscopic treatment of acute bleeding and follow-up for both gastro-duodenal ulcers and portal hypertension-induced bleeding.
Chronic pancreatitis (CP) is an inflammatory disorder characterized by inflammation and fibrosis, resulting in a progressive and irreversible destruction of exocrine and endocrine pancreatic tissue. Clinicians should attempt to classify patients into one of the six etiologic groups according to the TIGARO classification system. MRI/MRCP, if possible with secretin enhancement, is considered the imaging modality of choice for the diagnosis of early-stage disease.In CP, pain is the most disabling symptom, with a significant impact on quality of life. Pain should be assessed using the Izbicki score and preferably treated using the "pain ladder" approach. In painful CP, endoscopic therapy (ET) can be considered as early as possible. This procedure can be combined with extracorporeal shock-wave lithotripsy (ESWL) in the presence of large (> 4 mm), obstructive stone(s) in the pancreatic head, and with ductal stenting in the presence of a single main pancreatic duct (MPD) stricture in the pancreatic head with a markedly dilated MPD. Pancreatic stenting should be pursued for at least 12 months in patients with persistent pain relief. On-demand stent exchange should be the preferred strategy. The simultaneous placement of multiple, side-by-side, pancreatic stents can be recommended in patients with MPD strictures persisting after 12 months of single plastic stenting. We recommend surgery in the following cases: a) technical failure of ET ; b) early (6 to 8 weeks) clinical failure ; c) definitive biliary drainage at a later time point; d) pancreatic ductal drainage when repetitive ET is considered unsuitable for young patients; e) resection of an inflammatory pancreatic head when pancreatic cancer cannot be ruled out; f) duodenal obstruction. Duodenopancreatectomy or oncological distal pancreatectomy should be considered for patients with suspected malignancy. Pediatricians should be aware of and systematically search for CP in the differential diagnosis of chronic abdominal pain. As malnutrition is highly prevalent in CP patients, patients at nutritional risk should be identified in order to allow for dietary counseling and nutritional intervention using oral supplements. Patients should follow a healthy balanced diet taken in small meals and snacks, with normal fat content. Enzyme replacement therapy is beneficial to symptomatic patients, but also in cases of subclinical insufficiency. Regular follow-up should be considered in CP patients, primarily to detect subclinical maldigestion and the development of pancreatogenic diabetes. Screening for pancreatic cancer is not recommended in CP patients, except in those with the hereditary form.
Non-Alcoholic Fatty Liver Disease (NAFLD) is highly prevalent and associated with considerable liver-related and non-liverrelated morbidity and mortality. There is, however, a lot of uncertainty on how to handle NAFLD in clinical practice. The current guidance document, compiled under the aegis of the Belgian Association for the Study of the Liver by a panel of experts in NAFLD, from a broad range of different specialties, covers many questions encountered in daily clinical practice regarding diagnosis, screening, therapy and follow-up in adult and paediatric patients. Guidance statements in this document are based on the available evidence whenever possible. In case of absence of evidence or inconsistency of the data, guidance statements were formulated based on consensus of the expert panel. This guidance document is intended as a help for clinicians (general practitioners and all involved specialties) to implement the most recent evidence and insights in the field of NAFLD within a Belgian perspective.
Acta Gastro-Enterologica Belgica
Current issue Read more View all previous issues Open access journal This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Editorial board View our board Partners Acta Gastro-Enterologica Belgica is the official publication of the following national societies: Sponsors Acta Gastro-Enterologica Belgica … Home Read More »
The Belgian Helicobacter and Microbiota Study Group (BHMSG) welcomes the publication of their new Belgian consensus on the treatment of Helicobacter pylori (Hp) in the Acta Gastro-Enterologica Belgica. Vol 86, January-March (74-91), 2023 (1). We carried out a survey through a questionnaire on the treatment habits of Belgian practitioners at the end of 2020. This 30 questions survey was distributed through the Belgian professional associations of gastroenterology and general practitioners. 138 responses were received in total, including 95 Belgian and 43 African physicians.
Per- and polyfluoroalkyl substances (PFAS) are a diverse class of highly persistent anthropogenic chemicals that are detectable in the serum of most humans. PFAS exposure has been associated with many adverse effects on human health including immunotoxicity, increased risk of certain cancers, and metabolic disruption. PFAS binding to the most abundant blood serum proteins (human serum albumin [HSA] and globulins) is thought to affect transport to active sites, toxicity, and elimination half-lives. However, few studies have investigated the competitive binding of PFAS to these proteins in human serum. Here, we use C18 solid-phase microextraction fibers to measure HSA–water and globulin–water distribution coefficients ( D HSA/w, D glob/w ) for PFAS with carbon chains containing 4 to 13 perfluorinated carbons (η pfc = 4–13) and several functional head-groups. PFAS with η pfc < 7 were highly bound to HSA relative to globulins, whereas PFAS with η pfc ≥ 7 showed a greater propensity for binding to globulins. Experimentally measured D HSA/w and D glob/w and concentrations of serum proteins successfully predicted the variability in PFAS binding in human serum. We estimated that the unbound fraction of serum PFAS varied by up to a factor of 2.5 among individuals participating in the 2017–2018 U.S. National Health and Nutrition Examination Survey. These results suggest that serum HSA and globulins are important covariates for epidemiological studies aimed at understanding the effects of PFAS exposure.
暂无摘要（点击查看原文获取完整内容）
Purpose. The clinical utility of plasma methylated septin 9 (mSEPT9) DNA in screening and recurrence monitoring for colorectal cancer (CRC) is highly promising. The present study was performed to determine the diagnostic value of mSEPT9 in CRC detection and recurrence monitoring in Chinese patients. Methods. Overall, 616 patients newly diagnosed with CRC and 122 individuals with no evidence of disease were recruited from October 1, 2019, to May 31, 2021, at Fujian Medical University Union Hospital. Plasma and serum samples were collected for analyzing mSEPT9, carcinoembryonic antigen (CEA), and carbohydrate antigen-19-9 (CA19-9). Data on clinicopathological characteristics were collected and analyzed. Sensitivity and specificity were calculated to evaluate the diagnostic potential of each marker; the receiver operating characteristic (ROC) curve was applied for the assessment of diagnostic value, and comparisons among mSEPT9, CEA, CA19-9, and their combination were assessed via ROC curves. Results. mSEPT9 achieved an overall sensitivity and specificity of 72.94% and 81.97%, respectively, with an area under the curve (AUC) value of 0.826, which were higher than those of CEA (sensitivity: 43.96%; specificity: 96.72%; AUC: 0.789) and CA19-9 (sensitivity: 14.99%; specificity: 96.61%; AUC: 0.590). The combination of mSEPT9, CEA, and CA19-9 further improved sensitivity, specificity, and AUC value (sensitivity: 78.43%; specificity: 86.07%; AUC: 0.878), respectively. Notably, the mSEPT9 positivity rate was significantly associated with TNM stage, T stage, N stage, tumor size, vascular invasion, and nerve invasion among patients with CRC. A 100% correlation was observed between the positive results of the mSEPT9 test and recurrence or metastasis in patients after therapeutic intervention. Conclusion. Our findings suggest that mSEPT9 may represent a potential biomarker for the diagnosis and prognosis of CRC compared with CEA and CA19-9. Postoperative mSEPT9 status may represent the first noninvasive marker of CRC recurrence or metastasis.
In the previous issue of Acta Gastro-Enterologica Belgica, a meta-analysis on the presence of gastrointestinal (GI) symptoms in patients with COVID-19 was published (1). The pooled prevalence of GI manifestations was 12% with diarrhea being the most frequent digestive symptom (8%). Other reports show an incidence rate of diarrhea ranging from 2% to 50%. A question emerges after reading this systematic review : is the presence of these GI symptoms associated with a particular prognosis?